H.Res. 1179 · 111th Congress
Expressing the sense of the House of Representatives that biotechnology firms meeting small business standards are critical to the United States, its people and its economy because they create new medicines, services, and jobs and meet unmet needs related to populations and patients with infectious and chronic diseases, including those of medically underserved populations.
- Stage
- In committee
- Sponsor
- Danny Davis
- Introduced
- 2010-03-12
- Latest action
- 2010-03-12 · Introduced in House
Subjects
Executive agency funding and structure
Health
Infectious and parasitic diseases
Medical research
Advisory bodies
Department of Health and Human Services
Health technology, devices, supplies
Research and development
Small business
Technology transfer and commercialization
Public-private cooperation
Drug safety, medical device, and laboratory regulation